ANI Pharmaceuticals Inc
NASDAQ:ANIP
ANI Pharmaceuticals Inc
Cash from Operating Activities
ANI Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
Cash from Operating Activities
$119m
|
CAGR 3-Years
98%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
See Also
What is ANI Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
119m
USD
Based on the financial report for Dec 31, 2023, ANI Pharmaceuticals Inc's Cash from Operating Activities amounts to 119m USD.
What is ANI Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
12%
The average annual Cash from Operating Activities growth rates for ANI Pharmaceuticals Inc have been 98% over the past three years , 12% over the past five years .